MARSHALL WACE, LLP

Position in ZNTL — Zentalis Pharmaceuticals, Inc.

CIK 1318757 LONDON, X0

Position in ZNTL

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$2,868,644

+$1,949,861 QoQ

Shares Held

591,473

+50.6% QoQ

Ownership

0.825%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#23

of 114 holders

Holding Since

Jun 2023

10 quarters on record

Voting authority Sole 0% Shared 100% None 0%

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. ZNTL ranks #125 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	543,897	$270,169,956
2	INCY	Incyte Corp	1,310,154	$148,519,056
3	RPRX	Royalty Pharma plc	2,450,669	$137,409,009
4	SYRE	Spyre Therapeutics, Inc.	991,693	$88,042,503
5	ALNY	Alnylam Pharmaceuticals, Inc.	259,799	$78,207,292
6	TVTX	Travere Therapeutics, Inc.	1,333,207	$75,739,488
7	MANE	Veradermics, Inc	585,560	$71,988,746
8	DFTX	Definium Therapeutics, Inc.	1,298,946	$61,102,419

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$2,868,644	591,473	+50.6%	Shares	Other	2026-08-13
2026-03-31	$918,783	392,643	+58.5%	Shares	Other	2026-05-15
2025-12-31	$334,513	247,788	+178.4%	Shares	Other	2026-02-13
2024-12-31	$269,706	89,012	0.0%	Shares	Other	2025-02-13
2024-09-30	$327,564	89,012	0.0%	Shares	Other	2024-11-14
2024-06-30	$364,059	89,012	0.0%	Shares	Other	2024-08-14
2024-03-31	$1,402,829	89,012	0.0%	Shares	Other	2024-05-15
2023-12-31	$1,348,531	89,012	-67.1%	Shares	Other	2024-02-14
2023-09-30	$5,433,010	270,838	-47.5%	Shares	Other	2023-11-14
2023-06-30	$14,557,628	516,045	—	Shares	Other	2023-08-14
No filing history on record for this holder in this stock.